Alnylam's Q1 2026 revenue exceeded $1 billion primarily due to strong growth in its ATTR/TTR franchise, driven by AMVUTTRA's continued uptake and robust commercial execution. The growth was supported by high patient adherence and expanded market access.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What were the key drivers behind Alnylam's revenue surpassing $1 billion in Q1 2026?
Alnylam’s first-quarter 2026 revenue milestone—more than $1 billion in combined net product revenues—was primarily driven by strong underlying commercial execution in its ATTR/TTR franchise, especially continued uptake of AMVUTTRA. 12
Alnylam reported $1.036 billion in combined net product revenues in Q1 2026, which represented +121% year-over-year (and +4% vs. Q4 2025). 1
Management explicitly tied this growth to “the continued uptake of AMVUTTRA and ATTR cardiomyopathy,” and noted $910 million of Q1 TTR revenue. 2
Within TTR:
Management emphasized that revenue performance was supported by durable commercial fundamentals:
These factors matter because revenue growth for chronic, quarterly-dosed therapies tends to depend on sustained patient utilization rather than one-time events. (Management’s emphasis on adherence and pull-through aligns with that.) 1
While TTR was the dominant growth engine, Alnylam also reported consistent performance in its rare disease portfolio:
This provided additional revenue breadth alongside the TTR franchise. 1
The $1B milestone was specifically described as net product revenues, not total revenue broadly. 1
From the P&L summary:
Management acknowledged headwinds from pricing updates—particularly in Germany—but framed Q1 as stronger than expected:
This context supports the conclusion that the $1B net product revenue outcome reflected continued growth momentum, not merely timing or one-off offsets. 1245
Alnylam’s Q1 2026 surpassing $1 billion in net product revenues was driven chiefly by continued AMVUTTRA uptake within its TTR/ATTR franchise, evidenced by $910 million in TTR revenue and large year-over-year growth, supported by strong access/pull-through and >90% adherence in the U.S. 12
The result also benefited from additional rare disease revenue growth ($126 million), while collaboration revenue declined due to prior-year milestone timing effects. 12
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Alnylam lowers its 2026 revenue midpoint but emphasizes that strong H2 execution is essential to hitting revised targets, while reaffirming its commitment to a 25% CAGR through 2030. The discussion frames first-line momentum and an sizable untreated patient population as the key drivers, with second-line normalization reshaping near-term growth composition rather than undermining long-term prospects.
Sources used
Research questionHow will the updated 2026 guidance affect the 12- to 24-month outlook and the long-term goal of a 25% CAGR through 2030, given the guidance midpoint implies stronger H2 growth?
Answer outline
NVIDIA's management highlighted the upcoming Vera Rubin system's launch in Q3, emphasizing supply constraints and significant market opportunities driven by a $200 billion TAM and strong customer demand.
Sources used
Research questionWhat did management say about Vera Rubin Supply and Revenue?
Answer outline
TurboTax Live continues to exhibit strong growth driven by market share gains, customer acquisition, and monetization strategies, positioning for sustainable momentum.
Sources used
Research questionWhat are the main drivers behind TurboTax Live’s 38% customer growth and 36% revenue growth, and how does management plan to sustain that momentum?
Answer outline
Payoneer experienced a significant 44% year-over-year B2B volume growth in Q1 2026, driven by regional expansion, increased multi-product adoption, and strong customer onboarding in key markets like China and EMEA.
Sources used
Research questionWhat drove the 44% year-over-year B2B volume growth in Q1?
Answer outline
IonQ achieved exceptional revenue growth in Q1 2026, driven by strategic market expansion and product diversification. The company emphasizes scaling manufacturing, international growth, and leveraging application-layer partnerships to sustain momentum.
Sources used
Research questionWhat are IonQ's revenue growth projections and sales strategies for Q1 2026?
Answer outline
Remitly's Q1 2026 revenues outperformed guidance driven by demand tailwinds, record customer acquisition, and geopolitical surge in Middle East corridors, supported by strong operational metrics.
Sources used
Research questionWhat factors drove Q1 revenue to exceed the midpoint of guidance?
Answer outline
ACI Worldwide achieved a 39% increase in net new ARR bookings in Q1 2026, primarily driven by strong growth in the Biller segment, new contract wins, and expansion of SaaS offerings such as Speedpay One, across diverse verticals.
Sources used
Research questionWhat drove the 39% increase in net new ARR bookings in Q1?
Answer outline
This analysis provides insights into the customer mix behind DRS installations at Brink's during Q1 2026, highlighting the balance between customer conversions and new customer acquisitions.
Sources used
Research questionWhat proportion of DRS installs came from customer conversions versus new or previously vended customers?
Answer outline
Gulfport's Q1 2026 report highlights strong demand, robust backlog, and strategic capital moves, including sale-leasebacks and thoughtful capital allocation.
Sources used
Research questionHow did Gulfport balance discretionary acreage purchases versus share repurchases in Q1 2026?
Answer outline
This discussion explores how Fiserv plans to leverage AI investments and capital expenditures to achieve its targeted revenue growth in 2026, emphasizing strategic financial allocations and technological advancements.
Sources used
Research questionHow does Fiserv plan to leverage AI spend and capital expenditures to achieve its mid-single-digit revenue growth in 2026?
Answer outline
AMG achieved record earnings in Q1 2026 driven by strong client inflows, investment performance, margin improvements, and share repurchases, demonstrating diversified growth amid market volatility.
Sources used
Research questionWhat factors contributed to AMG's record earnings growth in Q1 2026?
Answer outline
Virtu's Q1 2026 performance was driven by favorable market conditions, robust market-making, strategic capital expansion, and momentum in execution services.
Sources used
Research questionWhat were the main drivers of the strong Q1 performance across Virtu’s businesses?
Answer outline
Dafinchi